Figure 4.Trial sequential analysis of objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) for bevacizumab-induced hypertension in patients with metastatic colorectal cancer.
Figure 4 — Usefulness of bevacizumab-induced hypertension in patients with metastatic colorectal cancer: an updated meta-analysis | Aging
